Sep 11, 2018
Tafsir al-'Alaq Ayat 3 (2/3) - Daulah Prof Chuzaimah Batubara in Fazih Sar, Persatuan Sarikat Islam dan Taklimatkan, dan Aktivitas Jabatan.
Rujukan Utama. Pengantar Studi Islam. DIE HENING Kontrak Belajar dan Peta Pembelajaran PSI Pertemuan 1. Dibuka surat Al'Alaq Ayat 1-5.
Category:Tafsir worksEfficacy and safety of imatinib and of nilotinib in treatment of chronic myeloid leukemia.
The objective of this study was to evaluate the efficacy and safety of imatinib and of nilotinib in chronic myeloid leukemia (CML) and accelerated phase chronic myeloid leukemia (AP-CML). Seventy patients with CML and three patients with AP-CML received imatinib (n = 32) or nilotinib (n = 38) for 18 months. The median duration of the chronic phase (CP) and the accelerated phase (AP) were 61 and 24 months, respectively. The overall response rate was 96% for the CP and 93% for the AP. Four patients (7%) with the CP progressed to blast crisis (BC) and three (8%) with the AP to accelerated phase (AP-CML). The best response to imatinib was hematological (hematological complete response in 95% and major cytogenetic response in 50%), while the best response to nilotinib was cytogenetic (major cytogenetic response in 75% and complete hematologic response in 90%). The median duration of the CP and AP were not significantly different for imatinib (60 and 24 months, respectively) and nilotinib (75 and 24 months, respectively). The overall survival in CML was significantly longer for imatinib (95 months) compared with nilotinib (60 months, P = 0.02). Imatinib was significantly more effective than nilotinib in treating CML and AP-CML, although the difference was not significant in CML patients with the t(9;22) translocation. The efficacy of nilotinib was lower than that of imatinib and its use was associated with a higher rate of adverse events.. The United States made a similar request in ac619d1d87
Related links:
Komentarze